Targeting Human Telomerase in Cancer: Therapeutic Limitations and New Opportunities

Authors

DOI:

https://doi.org/10.66505/cbtt.v1i4.66

Keywords:

Telomerase, telomere maintenance, telomerase reverse transcriptase (TERT), telomerase inhibitors, BIBR1532, structure-guided drug design

Abstract

Telomerase reactivation sustains telomere maintenance in most human cancers, making the enzyme an attractive therapeutic target. However, the clinical development of telomerase inhibitors has been constrained by delayed responses, toxicity in normal proliferative tissues, and incomplete understanding of inhibitor binding to human telomerase. Structural studies of insect TERT-like proteins, ciliate and yeast holoenzymes, and human telomerase have clarified the organization of the catalytic machinery and the conformational changes required for telomeric repeat synthesis. A recent series of nine cryo-electron microscopy structures of human telomerase, with and without BIBR1532, identified an inhibitor-binding pocket between the TERT finger and palm regions. These structures revealed how BIBR1532 interferes with template-DNA duplex repositioning, providing a mechanistic explanation for its inhibition of repeat-addition processivity. Importantly, the human binding site differs substantially from the pocket previously identified in an insect TERT-like protein, illustrating the limitations of extrapolating inhibitor recognition across species. This Review integrates advances in telomerase structural biology with the therapeutic development of RNA-template antagonists, nucleotide analogs, and direct TERT inhibitors. We critically examine the translational limitations of these approaches, including the gap between biochemical inhibition and antitumor efficacy. Finally, we discuss how the newly characterized human TERT pocket could inform medicinal chemistry and computational drug design, while identifying the experimental and clinical evidence needed to establish its therapeutic potential.

References

1. Olovnikov AM. A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol. 1973;41(1):181-190. doi:10.1016/0022-5193(73)90198-7

2. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell. 1985;43(2 Pt 1):405-413. doi:10.1016/0092-8674(85)90170-9

3. de Lange T. Shelterin-mediated telomere protection. Annu Rev Genet. 2018;52:223-247. doi:10.1146/annurev-genet-032918-021921

4. Shay JW, Wright WE. Telomeres and telomerase: three decades of progress. Nat Rev Genet. 2019;20(5):299-309. doi:10.1038/s41576-019-0099-1

5. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature. 1990;345(6274):458-460. doi:10.1038/345458a0

6. Takai H, Aria V, Borges P, Yeeles JTP, de Lange T. CST-polymerase α-primase solves a second telomere end-replication problem. Nature. 2024;627(8004):664-670. doi:10.1038/s41586-024-07137-1

7. Chakravarti D, LaBella KA, DePinho RA. Telomeres: history, health, and hallmarks of aging. Cell. 2021;184(2):306-322. doi:10.1016/j.cell.2020.12.028

8. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature. 2003;426(6963):194-198. doi:10.1038/nature02118

9. Maciejowski J, Li Y, Bosco N, Campbell PJ, de Lange T. Chromothripsis and kataegis induced by telomere crisis. Cell. 2015;163(7):1641-1654. doi:10.1016/j.cell.2015.11.054

10. Roake CM, Artandi SE. Regulation of human telomerase in homeostasis and disease. Nat Rev Mol Cell Biol. 2020;21(7):384-397. doi:10.1038/s41580-020-0234-z

11. Schmidt JC, Cech TR. Human telomerase: biogenesis, trafficking, recruitment, and activation. Genes Dev. 2015;29(11):1095-1105. doi:10.1101/gad.263863.115

12. Barthel FP, Wei W, Tang M, Martinez-Ledesma E, Hu X, Amin SB, et al. Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nat Genet. 2017;49(3):349-357. doi:10.1038/ng.3781

13. Sharma S, Chowdhury S. Emerging mechanisms of telomerase reactivation in cancer. Trends Cancer. 2022;8(8):632-641. doi:10.1016/j.trecan.2022.03.005

14. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266(5193):2011-2015. doi:10.1126/science.7605428

15. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339(6122):959-961. doi:10.1126/science.1230062

16. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339(6122):957-959. doi:10.1126/science.1229259

17. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013;110(15):6021-6026. doi:10.1073/pnas.1303607110

18. Bell RJ, Rube HT, Kreig A, Mancini A, Fouse SD, Nagarajan RP, et al. Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science. 2015;348(6238):1036-1039. doi:10.1126/science.aab0015

19. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. doi:10.1158/2159-8290.Cd-21-1059

20. Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E, et al. Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol. 2011;179(4):1608-1615. doi:10.1016/j.ajpath.2011.06.018

21. He Y, Feigon J. Telomerase structural biology comes of age. Curr Opin Struct Biol. 2022;76:102446. doi:10.1016/j.sbi.2022.102446

22. Theimer CA, Blois CA, Feigon J. Structure of the human telomerase RNA pseudoknot reveals conserved tertiary interactions essential for function. Mol Cell. 2005;17(5):671-682. doi:10.1016/j.molcel.2005.01.017

23. Zhang Q, Kim NK, Feigon J. Architecture of human telomerase RNA. Proc Natl Acad Sci U S A. 2011;108(51):20325-20332. doi:10.1073/pnas.1100279108

24. Jurczyluk J, Nouwens AS, Holien JK, Adams TE, Lovrecz GO, Parker MW, et al. Direct involvement of the TEN domain at the active site of human telomerase. Nucleic Acids Res. 2011;39(5):1774-1788. doi:10.1093/nar/gkq1083

25. Theimer CA, Jády BE, Chim N, Richard P, Breece KE, Kiss T, et al. Structural and functional characterization of human telomerase RNA processing and Cajal body localization signals. Mol Cell. 2007;27(6):869-881. doi:10.1016/j.molcel.2007.07.017

26. Chen G, Wen JD, Tinoco I Jr. Single-molecule mechanical unfolding and folding of a pseudoknot in human telomerase RNA. RNA. 2007;13(12):2175-2188. doi:10.1261/rna.676707

27. Chen JL, Greider CW. Functional analysis of the pseudoknot structure in human telomerase RNA. Proc Natl Acad Sci U S A. 2005;102(23):8080-8085. doi:10.1073/pnas.0502259102

28. Gillis AJ, Schuller AP, Skordalakes E. Structure of the Tribolium castaneum telomerase catalytic subunit TERT. Nature. 2008;455(7213):633-637. doi:10.1038/nature07283

29. Mitchell M, Gillis A, Futahashi M, Fujiwara H, Skordalakes E. Structural basis for telomerase catalytic subunit TERT binding to RNA template and telomeric DNA. Nat Struct Mol Biol. 2010;17(4):513-518. doi:10.1038/nsmb.1777

30. Bryan C, Rice C, Hoffman H, Harkisheimer M, Sweeney M, Skordalakes E. Structural basis of telomerase inhibition by the highly specific BIBR1532. Structure. 2015;23(10):1934-1942. doi:10.1016/j.str.2015.08.006

31. Choi WS, Weng PJ, Yang W. Flexibility of telomerase in binding the RNA template and DNA telomeric repeat. Proc Natl Acad Sci U S A. 2022;119(1):e2116159118. doi:10.1073/pnas.2116159118

32. Wang Y, Gallagher-Jones M, Sušac L, Song H, Feigon J. A structurally conserved human and Tetrahymena telomerase catalytic core. Proc Natl Acad Sci U S A. 2020;117(49):31078-31087. doi:10.1073/pnas.2011684117

33. Jiang J, Miracco EJ, Hong K, Eckert B, Chan H, Cash DD, et al. The architecture of Tetrahymena telomerase holoenzyme. Nature. 2013;496(7444):187-192. doi:10.1038/nature12062

34. Jiang J, Chan H, Cash DD, Miracco EJ, Ogorzalek Loo RR, Upton HE, et al. Structure of Tetrahymena telomerase reveals previously unknown subunits, functions, and interactions. Science. 2015;350(6260):aab4070. doi:10.1126/science.aab4070

35. Jiang J, Wang Y, Sušac L, Chan H, Basu R, Zhou ZH, et al. Structure of telomerase with telomeric DNA. Cell. 2018;173(5):1179-1190.e13. doi:10.1016/j.cell.2018.04.038

36. He Y, Wang Y, Liu B, Helmling C, Sušac L, Cheng R, et al. Structures of telomerase at several steps of telomere repeat synthesis. Nature. 2021;593(7859):454-459. doi:10.1038/s41586-021-03529-9

37. Sauerwald A, Sandin S, Cristofari G, Scheres SHW, Lingner J, Rhodes D. Structure of active dimeric human telomerase. Nat Struct Mol Biol. 2013;20(4):454-460. doi:10.1038/nsmb.2530

38. Nguyen THD, Tam J, Wu RA, Greber BJ, Toso D, Nogales E, et al. Cryo-EM structure of substrate-bound human telomerase holoenzyme. Nature. 2018;557(7704):190-195. doi:10.1038/s41586-018-0062-x

39. Ghanim GE, Fountain AJ, van Roon AM, Rangan R, Das R, Collins K, et al. Structure of human telomerase holoenzyme with bound telomeric DNA. Nature. 2021;593(7859):449-453. doi:10.1038/s41586-021-03415-4

40. Wan F, Ding Y, Zhang Y, Wu Z, Li S, Yang L, et al. Zipper head mechanism of telomere synthesis by human telomerase. Cell Res. 2021;31(12):1275-1290. doi:10.1038/s41422-021-00586-7

41. Liu B, He Y, Wang Y, Song H, Zhou ZH, Feigon J. Structure of active human telomerase with telomere shelterin protein TPP1. Nature. 2022;604(7906):578-583. doi:10.1038/s41586-022-04582-8

42. Sekne Z, Ghanim GE, van Roon AM, Nguyen THD. Structural basis of human telomerase recruitment by TPP1-POT1. Science. 2022;375(6585):1173-1176. doi:10.1126/science.abn6840

43. Ghanim GE, Sekne Z, Balch S, van Roon AM, Nguyen THD. 2.7 Å cryo-EM structure of human telomerase H/ACA ribonucleoprotein. Nat Commun. 2024;15(1):746. doi:10.1038/s41467-024-45002-x

44. Balch S, Sekne Z, Franco-Echevarría E, Ludzia P, Kretsch RC, Sun W, et al. Cryo-EM structure of human telomerase dimer reveals H/ACA RNP-mediated dimerization. Science. 2025;389(6756):eadr5817. doi:10.1126/science.adr5817

45. Hu H, Neumann H, Teplitz GM, Franco-Echevarría E, Chartrand P, Wellinger RJ, et al. Cryo-electron microscopy structure of the budding yeast telomerase holoenzyme. Science. 2026;391(6792):eadz5344. doi:10.1126/science.adz5344

46. Balch S, Franco-Echevarría E, Ghanim GE, Kretsch RC, Das R, Nguyen THD. Structures of nucleotide-bound human telomerase at several steps of its telomeric DNA repeat addition cycle. Nat Commun. 2026;17(1):1847. doi:10.1038/s41467-026-68560-8

47. Chen Y, Podlevsky JD, Logeswaran D, Chen JJ. A single nucleotide incorporation step limits human telomerase repeat addition activity. EMBO J. 2018;37(6):e97953. doi:10.15252/embj.201797953

48. Siteni S, Grichuk A, Shay JW. Telomerase in cancer therapeutics. Cold Spring Harb Perspect Biol. 2024;16(12):a041703. doi:10.1101/cshperspect.a041703

49. Wang Y, Liu B, He Y, Feigon J. Structures of human telomerase with BIBR1532 reveal novel mechanism of inhibition. Nat Chem Biol. 2026;22(11):1854-1862. doi:10.1038/s41589-026-02238-6

50. Kim N, Pulte ED, Ehrlich LA, Ionan AC, Haupert S, Vallejo J, et al. US Food and Drug Administration approval summary: imetelstat for selected patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. J Clin Oncol. 2025;43(35):3760-3768. doi:10.1200/JCO-25-01369

51. Kim MY, Vankayalapati H, Shin-Ya K, Wierzba K, Hurley LH. Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular G-quadruplex. J Am Chem Soc. 2002;124(10):2098-2099. doi:10.1021/ja017308q

52. Gridelli C, Ciuleanu T, Domine M, Szczesna A, Bover I, Cobo M, et al. Clinical activity of a hTERT (VX-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial. Br J Cancer. 2020;122(10):1461-1466. doi:10.1038/s41416-020-0785-y

53. Vinagre J, Almeida A, Pópulo H, Batista R, Lyra J, Pinto V, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013;4:2185. doi:10.1038/ncomms3185

54. Singh M, Wang Z, Koo BK, Patel A, Cascio D, Collins K, et al. Structural basis for telomerase RNA recognition and RNP assembly by the holoenzyme La family protein p65. Mol Cell. 2012;47(1):16-26. doi:10.1016/j.molcel.2012.05.018

55. Wang Y, He Y, Wang Y, Yang Y, Singh M, Eichhorn CD, et al. Structure of LARP7 protein p65-telomerase RNA complex in telomerase revealed by cryo-EM and NMR. J Mol Biol. 2023;435(11):168044. doi:10.1016/j.jmb.2023.168044

56. He Y, Song H, Chan H, Liu B, Wang Y, Sušac L, et al. Structure of Tetrahymena telomerase-bound CST with polymerase α-primase. Nature. 2022;608(7924):813-818. doi:10.1038/s41586-022-04931-7

57. Kim NK, Zhang Q, Zhou J, Theimer CA, Peterson RD, Feigon J. Solution structure and dynamics of the wild-type pseudoknot of human telomerase RNA. J Mol Biol. 2008;384(5):1249-1261. doi:10.1016/j.jmb.2008.10.005

58. Leeper TC, Varani G. The structure of an enzyme-activating fragment of human telomerase RNA. RNA. 2005;11(4):394-403. doi:10.1261/rna.7222505

59. Wang Y, Yesselman JD, Zhang Q, Kang M, Feigon J. Structural conservation in the template/pseudoknot domain of vertebrate telomerase RNA from teleost fish to human. Proc Natl Acad Sci U S A. 2016;113(35):E5125-E5134. doi:10.1073/pnas.1607411113

60. Herbert BS, Pongracz K, Shay JW, Gryaznov SM. Oligonucleotide N3′→P5′ phosphoramidates as efficient telomerase inhibitors. Oncogene. 2002;21(4):638-642. doi:10.1038/sj.onc.1205064

61. Herbert BS, Gellert GC, Hochreiter A, Pongracz K, Wright WE, Zielinska D, et al. Lipid modification of GRN163, an N3′ → P5′ thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene. 2005;24(33):5262-5268. doi:10.1038/sj.onc.1208760

62. Damm K, Hemmann U, Garin-Chesa P, Hauel N, Kauffmann I, Priepke H, et al. A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J. 2001;20(24):6958-6968. doi:10.1093/emboj/20.24.6958

63. Platzbecker U, Santini V, Fenaux P, Sekeres MA, Savona MR, Madanat YF, et al. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024;403(10423):249-260. doi:10.1016/s0140-6736(23)01724-5

64. Strahl C, Blackburn EH. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol. 1996;16(1):53-65. doi:10.1128/mcb.16.1.53

65. Mender I, Gryaznov S, Dikmen ZG, Wright WE, Shay JW. Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2'-deoxyguanosine. Cancer Discov. 2015;5(1):82-95. doi:10.1158/2159-8290.Cd-14-0609

66. Sanford SL, Badstübner M, Gerber M, Mannherz W, Lampl N, Dannenberg R, et al. Therapeutic 6-thio-deoxyguanosine inhibits telomere elongation in cancer cells by inducing a non-productive stalled telomerase complex. Nat Commun. 2026;17(1):6. doi:10.1038/s41467-025-66534-w

67. Pascolo E, Wenz C, Lingner J, Hauel N, Priepke H, Kauffmann I, et al. Mechanism of human telomerase inhibition by BIBR1532, a synthetic, non-nucleosidic drug candidate. J Biol Chem. 2002;277(18):15566-15572. doi:10.1074/jbc.M201266200

68. Al-Karmalawy AA, Nafie MS, Shaldam MA, Elmaaty AA, Antar SA, El-Hamaky AA, et al. Ligand-based design on the dog-bone-shaped BIBR1532 pharmacophoric features and synthesis of novel analogues as promising telomerase inhibitors with in vitro and in vivo evaluations. J Med Chem. 2023;66(1):777-792. doi:10.1021/acs.jmedchem.2c01668

69. Al-Karmalawy AA, Mousa MHA, Sharaky M, Mourad MAE, El-Dessouki AM, Hamouda AO, et al. Lead optimization of BIBR1591 to improve its telomerase inhibitory activity: design and synthesis of novel four chemical series with in silico, in vitro, and in vivo preclinical assessments. J Med Chem. 2024;67(1):492-512. doi:10.1021/acs.jmedchem.3c01708

70. Schneuing A, Harris C, Du Y, Didi K, Jamasb A, Igashov I, et al. Structure-based drug design with equivariant diffusion models. Nat Comput Sci. 2024;4(12):899-909. doi:10.1038/s43588-024-00737-x

71. Zou Y, Guo T, Fu Z, Guo Z, Bo W, Yan D, et al. A structure-based framework for selective inhibitor design and optimization. Commun Biol. 2025;8(1):422. doi:10.1038/s42003-025-07840-3

72. Peng X, Guo R, Guo F, Wang Z, Sun J, Guan J, et al. Unified modeling of 3D molecular generation via atomic interactions with PocketXMol. Cell. 2026;189(7):1904-1922.e28. doi:10.1016/j.cell.2026.01.003

Structural comparison of BIBR1532 binding in beetle and human telomerase, showing distinct ligand positions upon alignment. A human telomerase surface view and enlarged binding pocket highlight surrounding domains and amino acid residues.

Published

2026-11-14

How to Cite

1.
Wu Y, Song H. Targeting Human Telomerase in Cancer: Therapeutic Limitations and New Opportunities. Cancer Biome Target Ther. [Internet]. 2026 Nov. 14 [cited 2026 Nov. 16];1(4):279-301. Available from: https://cancerbiometherapy.com/index.php/cbtt/article/view/66

Issue

Section

Review

Funding data